Strength of the Pack: The Personalities, Politics and Espionage Intrigues. Douglas Valentine, 2010, ISBN 978-1-936296-91-0 (Google Books [abgerufen am 13. Mai 2018]).
Richard R. Abood: Pharmacy Practice and the Law. Jones & Bartlett, 2012, ISBN 978-1-4496-8691-8, The Closed System of Controlled Substance Distribution, S.184 (Google Books [abgerufen am 30. Dezember 2012]).
David T. Courtwright: The Controlled Substances Act: how a „big tent“ reform became a punitive drug law. In: Drug and Alcohol Dependence. Band76, Nr.1, 5. Oktober 2004, S.9–15, doi:10.1016/j.drugalcdep.2004.04.012, PMID 15380284.
Paul Gee, Mark Gilbert, Sandra Richardson, Grant Moore, Sharon Paterson, Patrick Graham: Toxicity from the Recreational Use of 1-benzylpiperazine. In: Clinical Toxicology. Band46, Nr.9, 2008, S.802–07, doi:10.1080/15563650802307602, PMID 18821145.
K. Brennan, A. Johnstone, P. Fitzmaurice, R. Lea, S. Schenk: Chronic Benzylpiperazine (BZP) Exposure Produces Behavioral Sensitization and Cross-sensitization to Methamphetamine (MA). In: Drug and Alcohol Dependence. Band88, Nr.2–3, 2007, S.204–13, doi:10.1016/j.drugalcdep.2006.10.016, PMID 17125936.
G. Tunnicliff: Sites of action of gamma hydroxybutyrate (GHB) – A neuroactive drug with abuse potential. In: Clinical Toxicology. Band35, Nr.6, 1997, S.581–590, doi:10.3109/15563659709001236.
J.H. Halpern: Hallucinogens and dissociative agents naturally growing in the United States. In: Pharmacology & Therapeutics. Band102, Nr.2, 2004, S.131–138, doi:10.1016/j.pharmthera.2004.03.003, PMID 15163594.
David J. Nutt, Leslie A. King, Lawrence D. Phillips Independent Scientific Committee on Drugs: Drug harms in the UK: A multicriteria decision analysis. In: The Lancet. Band376, Nr.9752, 6. November 2010, S.1558–1565, doi:10.1016/S0140-6736(10)61462-6, PMID 21036393.
DrugFacts: Is Marijuana Medicine? In: National Institute on Drug Abuse. National Institutes of Health; U.S. Department of Health and Human Services, Juli 2015; abgerufen im 1. Januar 1 (englisch).
druglibrary.net
Rufus King: The Drug Hang Up, America's Fifty-Year Folly. Schaffer Library of Drug Policy, The 1970 Act: Don't Sit There, Amend Something (Online).
druglibrary.org
Public Policy Options (= Canadian Senate Special Committee on Illegal Drugs. Band3). Schaffer Library of Drug Policy, The 1912 Hague International Opium Convention (Online).
Drug Enforcement Administration: Schedules of Controlled Substances: Placement of 5-Methoxy-N,N-Dimethyltryptamine Into Schedule I of the Controlled Substances Act. In: Federal Register. Band74, Nr.161, 21. August 2009, S.42217–42220: „Under the authority vested in the Attorney General by section 201(a) of the CSA (21 USC 811(a)), and delegated to the Administrator of DEA by Department of Justice regulations (28 CFR 0.100), and redelegated to the Deputy Administrator pursuant to 28 CFR 0.104…“FR 42217
Donnie Marshall: Notice of denial of petition to reschedule marijuana. In: Federal Register. Band66, Nr.75. Drug Enforcement Administration, 20. März 2001, S.20038–20076 (Online [abgerufen am 13. Juni 2013]).
gpo.gov
Federal Register / Vol. 79, No. 163 / Pgs. 49661 – 49682 / 22. August 2014 DEA-Final Rule, in Kraft ab 6. Oktober 2014 Text (162 KB)PDF (242 KB)
91. Kongress der Vereinigten Staaten: An Act to amend the Public Health Service Act and other laws to provide increased research, into, and prevention of, drug abuse and drug dependence; to provide for treatment and rehabilitation of drug abusers and drug dependent persons; and to strengthen existing law enforcement authority in the field of drug abuse. U.S. Government Publishing Office, 1970, Part F – Advisory Commission: Establishment of Commission on Marihuana and Drug Abuse, S.1280–1281.Pub.L.91-513, 84 Stat. 1236, erlassen am 27. Oktober 1970
nih.gov
ncbi.nlm.nih.gov
David T. Courtwright: The Controlled Substances Act: how a „big tent“ reform became a punitive drug law. In: Drug and Alcohol Dependence. Band76, Nr.1, 5. Oktober 2004, S.9–15, doi:10.1016/j.drugalcdep.2004.04.012, PMID 15380284.
Paul Gee, Mark Gilbert, Sandra Richardson, Grant Moore, Sharon Paterson, Patrick Graham: Toxicity from the Recreational Use of 1-benzylpiperazine. In: Clinical Toxicology. Band46, Nr.9, 2008, S.802–07, doi:10.1080/15563650802307602, PMID 18821145.
K. Brennan, A. Johnstone, P. Fitzmaurice, R. Lea, S. Schenk: Chronic Benzylpiperazine (BZP) Exposure Produces Behavioral Sensitization and Cross-sensitization to Methamphetamine (MA). In: Drug and Alcohol Dependence. Band88, Nr.2–3, 2007, S.204–13, doi:10.1016/j.drugalcdep.2006.10.016, PMID 17125936.
J.H. Halpern: Hallucinogens and dissociative agents naturally growing in the United States. In: Pharmacology & Therapeutics. Band102, Nr.2, 2004, S.131–138, doi:10.1016/j.pharmthera.2004.03.003, PMID 15163594.
David J. Nutt, Leslie A. King, Lawrence D. Phillips Independent Scientific Committee on Drugs: Drug harms in the UK: A multicriteria decision analysis. In: The Lancet. Band376, Nr.9752, 6. November 2010, S.1558–1565, doi:10.1016/S0140-6736(10)61462-6, PMID 21036393.
Federal Pseudoephedrine Law. In: doh.state.fl.us. Florida Department of Health, Division of Medical Quality Assurance, 5. Oktober 2006, archiviert vom Original am 30. Juli 2012; abgerufen am 20. Oktober 2012 (englisch).
Drug Scheduling. Drug Enforcement Administration, United States Department of Justice, archiviert vom Original am 9. August 2017; abgerufen im 1. Januar 1 (englisch).
Federal Pseudoephedrine Law. In: doh.state.fl.us. Florida Department of Health, Division of Medical Quality Assurance, 5. Oktober 2006, archiviert vom Original am 30. Juli 2012; abgerufen am 20. Oktober 2012 (englisch).
Drug Scheduling. Drug Enforcement Administration, United States Department of Justice, archiviert vom Original am 9. August 2017; abgerufen im 1. Januar 1 (englisch).
